Stockscreener 앱 받기
12.92
1.22%
-0.16
시간 외 거래:
12.92
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora Therapeutics Inc. (NMRA) Stock: A Year of Declines and Increases - The InvestChronicle
Taking on analysts’ expectations and winning: Neumora Therapeutics Inc. (NMRA) - SETE News
Neumora Therapeutics Inc. (NMRA) gets rating Initiated from Needham - Knox Daily
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.1% - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.1% - Defense World
Logos Global Management LP Has $2.95 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
A year in review: Neumora Therapeutics Inc. (NMRA)’s performance in the last year - US Post News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stake Cut by Logos Global Management LP - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rhumbline Advisers Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Rhumbline Advisers Grows Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Callan Capital LLC Boosts Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 30,788 Shares of Stock - Defense World
Callan Capital LLC Has $6.50 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells $363,606.28 in Stock - MarketBeat
Neumora Therapeutics' head of R&D sells over $490k in company stock - Investing.com Australia
Neumora Therapeutics' head of R&D sells over $490k in company stock - Investing.com Canada
Neumora Therapeutics' head of R&D sells over $490k in company stock - Investing.com
Neumora Therapeutics' head of R&D sells over $490k in company stock - Investing.com UK
SkyOak Wealth LLC Purchases Shares of 15,000 Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Shares Up 5.2% - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 5.2% - Defense World
NMRA (Neumora Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily
NMRA underperforms with a -0.75 decrease in share price - US Post News
Financial Metrics Unveiled: Neumora Therapeutics Inc. (NMRA)’s Key Ratios in the Spotlight - The Dwinnex
Bank of New York Mellon Corp Acquires 194,559 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Bank of New York Mellon Corp Grows Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Does Neumora Therapeutics Inc. (NMRA) offer a good opportunity for investors? - SETE News
Principal Financial Group Inc. Purchases New Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
TD Asset Management Inc Purchases 34,800 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
(NMRA) Long Term Investment Analysis - Stock Traders Daily
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Inc. [NMRA] Records 50-Day SMA of $11.52 - Knox Daily
Neumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Results from Neumora Therapeutics Inc. (NMRA) show risk - US Post News
Neumora Therapeutics Inc. (NMRA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Neumora Therapeutics (NASDAQ:NMRA) Trading Up 7.2% - MarketBeat
Neumora Therapeutics’ (NMRA) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Earns Outperform Rating from Royal Bank of Canada - MarketBeat
(NMRA) Technical Data - Stock Traders Daily
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Closing Bell Recap: Neumora Therapeutics Inc. (NMRA) Ends at 11.21, Reflecting a -3.11 Downturn - The Dwinnex
The Psychology of Neumora Therapeutics Inc. Inc. (NMRA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Neumora Therapeutics Inc. (NMRA) rating initates by Needham - Knox Daily
Neumora Therapeutics (NASDAQ:NMRA) Trading 2.6% Higher - MarketBeat
Commit To Purchase Neumora Therapeutics At $10, Earn 66.1% Annualized Using Options - Nasdaq
Neumora Therapeutics CFO sells $178,806 in company stock - Investing.com
Neumora Therapeutics CFO sells $178,806 in company stock By Investing.com - Investing.com Canada
Neumora Therapeutics, Inc. (NASDAQ:NMRA) CFO Joshua Pinto Sells 28,496 Shares of Stock - Defense World
Neumora Therapeutics CFO sells shares worth over $984k - Investing.com India
Calamos Advisors LLC Sells 17,604 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) CFO Joshua Pinto Sells 31,642 Shares - Defense World
Neumora Therapeutics CFO sells shares worth over $984k - Investing.com
Neumora Therapeutics CFO sells shares worth over $984k By Investing.com - Investing.com Australia
Unlocking Growth Opportunity In Neumora Therapeutics Inc. (NASDAQ: NMRA) - Stocks Register
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Down 5.7% - MarketBeat
SG Americas Securities LLC Makes New $566,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
SG Americas Securities LLC Invests $566,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.6% - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Vanguard Group Inc. - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Vanguard Group Inc. - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.6% - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) institutional investors have had a good week as stock gains 4.9% - Simply Wall St
10 neuroscience biotech companies you should know about - Labiotech.eu
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - StockTitan
Stock Surge: Neumora Therapeutics Inc. (NMRA) Closes at 11.24, Marking a -4.66 Increase/Decrease - The Dwinnex
Neumora Therapeutics Inc.: Rising -46.48% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
0.87%
자본화:
|
볼륨(24시간):